Printer Friendly

Albert Einstein wins USD12m NIH grant to fight against virulent viruses.

M2 EQUITYBITES-August 14, 2017-Albert Einstein wins USD12m NIH grant to fight against virulent viruses


Medical research company Albert Einstein College of Medicine reported on Friday the receipt of three NIH grants, valued at more than USD12m, for research to protect against three deadly viruses: Ebola, Marburg and hantavirus.

The research collaborations between Kartik Chandran, PhD, professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology, and Jonathan Lai, PhD, associate professor of biochemistry, have led to novel approaches for developing vaccines and treatments against Ebola, Marburg and hantavirus.

This first five-year, USD6m grant will support the development of the broadly active monoclonal antibody therapies (mAbs) against Ebola viruses.The Einstein researchers hope to develop one or more broadly neutralizing antibodies that work against all three types of Ebola. Drs Chandran and Lai are co-principal investigators on the project.

Under the second USD2.9m four year NIH grant, Dr Lai will develop a broadly neutralizing antibody therapy for Ebola and extend that strategy to Marburg virus, a deadly filovirus that is distantly related to Ebola. The Einstein researchers will explore whether this approach works against disease-causing viruses that are not filoviruses.

In conjunction, the Einstein researchers will use the third five year USD3.2m grant to support the research of hantaviruses, which is the deadly pathogens transmitted by rodent that enter the human body. Hantaviruses cause a highly fatal cardiopulmonary syndrome in the Americas and a less fatal, but more prevalent, hemorrhagic fever with renal complications in Europe and Asia.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 14, 2017
Previous Article:FCB Financial names Jack Partagas as new CFO.
Next Article:Efore reduces loss in H1 2017.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |